Searched for
IMMUNOLOGY PIPELINE
Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...
- Bristol Myers lines up many launches for India with 'AI' speedBristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doct...
- AstraZeneca's asthma drug fails 'smoker's lung' studyAstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the...
- AstraZeneca signs AI research deal with China's CSPC for chronic diseasesUnder Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule or...
- Sanofi buys US biopharma group Blueprint in $9.1 billion dealSanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt,...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Monthly milestones for Covaxin, Covishield to meet government’s 2-billion-dose targetET has reliably gathered that in discussions with the companies concerned Bharat Biotech has indicated to maintain a production of 75 milli...
- US-based Acasti Pharma to buy Indian origin pharma firm GraceAs per the understanding, Acasti will acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple pr...
- Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New ZealandCipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...
- Biocon to expand generic drugs business with DKSHAs a part of the pact, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various ther...
- Biocon Biologics debuts in Asia IP Elite listBiocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELI...
- Dr Reddy's launches Roche's Avastin biosimilar in IndiaThe launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio.
- Lupin developing new products to treat cancer, other diseasesSharing details, Kamboj said the the Mumbai-based company is currently working on developing various products, including two major ones to ...
- Dr Reddy's launches Hervycta to treat cancer in IndiaQuoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending...
- Over next 12-15 months, expect a lot of licensing activity: Glenn Saldanha, Glenmark“Everything is contingent now on getting new product approvals on time.”
- Glenmark, APC Therapeutics ink licensing pact for cancer drugUnder the terms of the agreement, Glenmark will license the product from APC Therapeutics and manage all clinical development, including re...
- Global private equity giants eye stake in Bharat BiotechHyderabad based biotechnology firm Bharat Biotech which recently claimed that it was probably the first company in the world to file global...
- Biogen for inlicensing deal with Indian cosUS-based biotech company Biogen Idec, is looking for partnerships across the pharma value chain, including in-licensing of new experimental...
Load More
